To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Axelar AB Presents Phase I/II Data of AXL1717 at the ASCO Annual Meeting
Axelar AB has announced the release of a poster at The American Society of Clinical Oncology (ASCO) Annual Meeting with data from the Phase I/II trial of AXL1717 that was completed in 2011.
The poster entitled “A novel targeted oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung cancer (NSCLC): A Phase I clinical trial.” is available on the Axelar and Karolinska Development websites (www.axelar.se and www.karolinskadevelopment.com).
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
